期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/ijms23031851
关键词
nanoparticle; neurodegenerative disorder; neurogenesis; Alzheimer's disease; Parkinson's disease; blood-brain barrier; amyotrophic lateral sclerosis
资金
- National Institute of Health [RO1 AG051574, RF1 AG068034]
- NIGMS COBRE award [1P20 GM109024]
- DaCCoTA CTR pilot feasibility [U54GM128729]
Neurodegenerative disorders are characterized by neuron loss. Most current treatments only alleviate associated symptoms due to the limited effectiveness of drugs crossing the blood-brain barrier. Nanoparticles offer a promising approach for targeted drug delivery to the brain.
Neurodegenerative disorders are primarily characterized by neuron loss. The most common neurodegenerative disorders include Alzheimer's and Parkinson's disease. Although there are several medicines currently approved for managing neurodegenerative disorders, a large majority of them only help with associated symptoms. This lack of pathogenesis-targeting therapies is primarily due to the restrictive effects of the blood-brain barrier (BBB), which keeps close to 99% of all foreign substances out of the brain. Since their discovery, nanoparticles have been successfully used for targeted delivery into many organs, including the brain. This review briefly describes the pathophysiology of Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis, and their current management approaches. We then highlight the major challenges of brain-drug delivery, followed by the role of nanotherapeutics for the diagnosis and treatment of various neurological disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据